The Mainstreaming Addiction Treatment Act and Pharmacist-Prescribed Buprenorphine

JAMA. 2025 Jul 15;334(3):269-271. doi: 10.1001/jama.2025.7151.

Authors

Emmy L Tran¹, S Michaela Rikard¹, Gery P Guy Jr¹, Christina A Mikosz¹

Affiliation

¹ Division of Overdose Prevention, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia.

No abstract available

Plain language summary

This study examines the impact of the MAT Act on trends in pharmacist-prescribed buprenorphine from US retail pharmacies from 2019 to 2024.

Grants and funding

CC999999/ImCDC/Intramural CDC HHS/United States